The United States Food and Drug Administration (FDA) has authorized the planet’s inaugural human clinical trials for a medication designed to counteract aging at the cellular foundation. This breakthrough was reported by the publication Nature Biotechnology.
Life Biosciences secured approval to proceed with Phase I testing of their gene therapy, designated ER-100, for individuals afflicted with severe, age-related ocular conditions.
ER-100 functions as a gene therapy. It employs a modified adeno-associated virus delivery system to introduce three specific genes into cells: OCT-4, SOX-2, and KLF-4. These genes are recognized as three of the four Yamanaka factors, which are instrumental in reprogramming mature cells.
By precisely regulating the activity of these genes, researchers endeavor to restore correct epigenetic markers within the cells. The desired outcome is for damaged or aged cells to revert to a more youthful profile, thereby regaining their functional capabilities.
The trials will initially enroll patients diagnosed with primary open-angle glaucoma and nonarteritic anterior ischemic optic neuropathy. These debilitating conditions are age-related eye diseases that frequently result in vision impairment. The primary objective of this initial phase is to ascertain the therapy’s safety and how well it is tolerated by patients.
Previous research involving this approach has already been conducted on mice and primates. In animal subjects, the treatment resulted in significant visual improvements, even when the optic nerve had sustained substantial damage.
About the Author
